HK1050625A1 - 取代的酰基氧肟酸和還原TNFα水平的方法 - Google Patents

取代的酰基氧肟酸和還原TNFα水平的方法 Download PDF

Info

Publication number
HK1050625A1
HK1050625A1 HK03101278.8A HK03101278A HK1050625A1 HK 1050625 A1 HK1050625 A1 HK 1050625A1 HK 03101278 A HK03101278 A HK 03101278A HK 1050625 A1 HK1050625 A1 HK 1050625A1
Authority
HK
Hong Kong
Prior art keywords
tnfα levels
acylhydroxamic acids
substituted acylhydroxamic
reducing tnfα
acids
Prior art date
Application number
HK03101278.8A
Other languages
English (en)
Chinese (zh)
Inventor
Man Hon-Wah
Muller George
Y. Huang Shaei
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of HK1050625A1 publication Critical patent/HK1050625A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK03101278.8A 1999-12-21 2000-12-19 取代的酰基氧肟酸和還原TNFα水平的方法 HK1050625A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/468,529 US6699899B1 (en) 1999-12-21 1999-12-21 Substituted acylhydroxamic acids and method of reducing TNFα levels
US09/468,529 1999-12-21
PCT/US2000/034455 WO2001045702A1 (en) 1999-12-21 2000-12-19 SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS

Publications (1)

Publication Number Publication Date
HK1050625A1 true HK1050625A1 (zh) 2003-07-04

Family

ID=23860180

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101278.8A HK1050625A1 (zh) 1999-12-21 2000-12-19 取代的酰基氧肟酸和還原TNFα水平的方法

Country Status (14)

Country Link
US (3) US6699899B1 (https=)
EP (1) EP1246620A4 (https=)
JP (1) JP2003518060A (https=)
KR (2) KR100831339B1 (https=)
CN (1) CN1413109A (https=)
AU (1) AU782634B2 (https=)
CA (1) CA2394604A1 (https=)
FI (1) FI20021193L (https=)
HK (1) HK1050625A1 (https=)
MX (1) MXPA02005840A (https=)
NO (2) NO323515B1 (https=)
NZ (1) NZ519638A (https=)
TW (2) TWI282788B (https=)
WO (1) WO2001045702A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
NZ334148A (en) * 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
EP2258363A1 (en) * 2002-05-17 2010-12-08 Celgene Corporation Compositions for treatment of cancers
CN1713905A (zh) * 2002-10-15 2005-12-28 细胞基因公司 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
MXPA05004777A (es) * 2002-11-06 2005-07-22 Celgene Corp Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
TW200501945A (en) 2002-11-06 2005-01-16 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
NZ540546A (en) * 2002-11-18 2008-03-28 Celgene Corp Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
EP1581205A1 (en) * 2002-11-18 2005-10-05 Celgene Corporation Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
BR0317885A (pt) * 2002-12-30 2005-12-06 Celgene Corp Composto, isÈmeros s e r enantiomericamente puros do mesmo, composição farmacêutica e métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa, de tratar ou prevenir mds, de tratar doença mieloproliferativa, angiogênese indesejada, câncer, uma doença, inflamação dos pulmões, depressão, distúrbio pulmonar obstrutivo crÈnico, doença inflamatória do intestino, dermatite atópica, psorìase, doença de crohn, artrite reumatóide, asma, eslcerose múltipla e doença cardìaca em um mamìfero e de tratar, prevenir ou controlar a sìndrome de dor regional complexa
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
DE602004032522D1 (de) * 2003-03-12 2011-06-16 Celgene Corp Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
JP4713465B2 (ja) 2003-03-12 2011-06-29 セルジーン コーポレイション ７−アミド−イソインドリル化合物およびその薬学的使用
CN100427465C (zh) * 2003-03-12 2008-10-22 细胞基因公司 N-烷基-异羟肟酸-异吲哚基化合物及其药物用途
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
CN101010298A (zh) * 2004-04-05 2007-08-01 默克Hdac研究有限责任公司 组蛋白脱乙酰酶抑制剂前药
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
MXPA06012279A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2006050057A2 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
WO2007134169A2 (en) * 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
KR20070092276A (ko) * 2004-12-13 2007-09-12 셀진 코포레이션 Ｐｄｅ４ 조절인자를 포함하는 조성물 및 이의 기도염의치료 또는 예방을 위한 용도
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
KR100608487B1 (ko) * 2006-05-08 2006-08-02 (주)거산기계 웨어 임펙트 플레이트가 장착된 외벽 함몰형 로터
MX2009006542A (es) * 2006-12-19 2009-06-30 Methylgene Inc Inhibidores de histona desacetilasa y sus profarmacos.
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
TWI519508B (zh) * 2007-06-12 2016-02-01 Achaogen Inc 抗菌劑
WO2009110947A2 (en) * 2007-12-19 2009-09-11 Alba Therapeutics Corporation Compositions and methods for inhibiting cytokine production
BRPI0802255A2 (pt) * 2008-06-17 2010-03-16 Sespo Ind E Com Ltda composição de uso tópico para controle de ectoparasitos em cães e gatos
CN101654427B (zh) * 2008-08-19 2012-12-05 信谊药厂 抗凝化合物、组合物及其用途
EP2395995A1 (en) * 2009-02-10 2011-12-21 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
MX341050B (es) 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
EP2583098B1 (en) 2010-06-15 2018-08-08 Celgene Corporation Biomarkers for the treatment of psoriasis
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
WO2017070291A1 (en) 2015-10-21 2017-04-27 Celgene Corporation Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)
CN105294533A (zh) * 2015-12-02 2016-02-03 宋彤云 一种治疗骨病的药物组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4173652A (en) 1976-12-18 1979-11-06 Akzona Incorporated Pharmaceutical hydroxamic acid compositions and uses thereof
SE434638B (sv) 1980-06-06 1984-08-06 Lekemedelsfabriken Medica Ab Nya terapeutiska verdefulla taurinderivat och deras framstellning
US4820828A (en) 1987-03-04 1989-04-11 Ortho Pharmaceutical Corporation Cinnamohydroxamic acids
JPH01153658A (ja) * 1987-12-08 1989-06-15 E R Squibb & Sons Inc ヘテロ含有置換基を有するフェニルヒドロキサム酸類
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
JPH0881443A (ja) * 1994-09-12 1996-03-26 Otsuka Pharmaceut Co Ltd 細胞外マトリックス金属プロテアーゼ阻害剤
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5719144A (en) * 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH0967331A (ja) * 1995-06-21 1997-03-11 Takeda Chem Ind Ltd 芳香族ヒドロキサム酸誘導体、その製造法および剤
CA2227237C (en) 1995-07-26 2005-12-13 Pfizer Inc. N-(aroyl)glycine hydroxamic acid derivatives and related compounds
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
PT871439E (pt) 1996-01-02 2004-08-31 Aventis Pharma Inc Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
NZ334148A (en) 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
HUP0003761A3 (en) * 1997-07-31 2001-04-28 Celgene Corp Warren Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
EP1030851B1 (en) * 1997-11-12 2005-01-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
JP4713465B2 (ja) * 2003-03-12 2011-06-29 セルジーン コーポレイション ７−アミド−イソインドリル化合物およびその薬学的使用

Also Published As

Publication number Publication date
TW200727895A (en) 2007-08-01
AU782634B2 (en) 2005-08-18
FI20021193A7 (fi) 2002-07-31
JP2003518060A (ja) 2003-06-03
US6699899B1 (en) 2004-03-02
AU2438901A (en) 2001-07-03
KR20070086919A (ko) 2007-08-27
WO2001045702A1 (en) 2001-06-28
NO323515B1 (no) 2007-06-04
NZ519638A (en) 2003-09-26
NO20022936L (no) 2002-08-14
TWI282788B (en) 2007-06-21
EP1246620A1 (en) 2002-10-09
US20080280967A1 (en) 2008-11-13
KR20020073145A (ko) 2002-09-19
CN1413109A (zh) 2003-04-23
TWI295925B (en) 2008-04-21
NO20071498L (no) 2002-08-14
FI20021193L (fi) 2002-07-31
US20040167174A1 (en) 2004-08-26
US7345062B2 (en) 2008-03-18
KR100831339B1 (ko) 2008-05-22
NO20022936D0 (no) 2002-06-18
MXPA02005840A (es) 2005-09-08
CA2394604A1 (en) 2001-06-28
EP1246620A4 (en) 2003-06-18

Similar Documents

Publication Publication Date Title
HK1050625A1 (zh) 取代的酰基氧肟酸和還原TNFα水平的方法
US5635517B1 (en) Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
NO996529D0 (no) Substituerte alkanohydroksamsyrer og metode for reduksjon av TNF<alfa>-nivåer
CA2261762A1 (en) Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
AU6092998A (en) 3-heterocyclyl-substituted benzoyl derivatives
AU2636897A (en) Carboxylic acid derivatives with an aggregation-inhibiting action
AU2358697A (en) Internal ultrasonic tip amplifier
AU6275198A (en) Soldering iron tip and method of making the same
AU2052800A (en) Metal and wood bat
DE69611706D1 (de) Niederdruckgiessanlage mit zwei Vorratsöfen
AU1078100A (en) Receiving terminal, method for controlling the same, and recorded medium on which program is recorded
WO2002052041A3 (en) 5' nuclease nucleic acid amplification assay having an improved internal control
AU3539199A (en) Novel 2,5-pyridinedicarboxylic acid derivatives
IL132175A (en) Method for producing aromatic aldehydes, 3-(2,4-dimethylphenyl)-butanal and the use thereof
ZA978877B (en) 3-Alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds.
FR2787145B1 (fr) Circuit d'injection perfectionne
IT1294897B1 (it) Procedimento per la produzione di tessere per mosaico dotate di aspetto anticato e tessere cosi' riprodotte.
PL321041A1 (en) 6-{triazolyl}[3-(trifluoromethyl)phenyl]methyl}2-quinolinones and-quinolinothiones
AU6119999A (en) An extended use-life improved tie
EP0638529A3 (en) Precursor amorphous carbon molded body.
AU2001224011A1 (en) Charging server, charging method, recorded medium where charging program is stored, and recorded medium where connection program is stored
AU1395100A (en) Ultrasonic resonator with slot of non-uniform width
CA2092526A1 (en) Contact pin with ceramic insulation
DK0929219T3 (da) Faste blandinger af 3-isopropyl-2,1,3-benzthiadiazin-4-on-2,2-dioxidsalte
NL1000652C2 (nl) Automatische hobo waarmee flageolettonen kunnen worden verkregen.